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Abstract
Vasodilator-stimulated phosphoprotein (VASP) is a processive actin polymerase with roles in the 
control of cell shape and cell migration. Through interaction with the cytoskeletal adaptor protein 
Zyxin, VASP can localize to damaged stress fibers where it serves to repair and reinforce these 
structures. VASP localization is mediated by its N-terminal Ena/VASP homology (EVH1) domain, 
which binds to the (W/F)PxφP motif (most commonly occurring as FPPPP) found in cytoskeletal 
proteins such as vinculin, lamellipodin, and Zyxin. Sequentially close clusters of four or five of 
these motifs frequently occur, as in the proline rich region of Zyxin with four such motifs. This 
suggests that tetrameric VASP might bind very tightly to Zyxin through avidity, with all four 
EVH1 domains binding to a single Zyxin molecule. Here, quantitative nuclear magnetic resonance 
titration analysis reveals a dominant bivalent 1:1 (Zyxin:EVH1) interaction between the Zyxin 
proline rich region and the VASP EVH1 domain that utilizes the EVH1 canonical binding site and 
a novel secondary binding site on the opposite face of the EVH1 domain. We further show that 
binding to the secondary binding site is specifically inhibited by mutation of VASP EVH1 domain 
residue Y39 to E, which mimics Abl-induced phosphorylation of Y39. On the basis of these 
findings, we propose a model in which phosphorylation of Y39 acts as a stoichiometry switch that 
governs binding partner selection by the constitutive VASP tetramer. These results have broader 
implications for other multivalent VASP EVH1 domain binding partners and for furthering our 
understanding of the role of Y39 phosphorylation in regulating VASP localization and cellular 
function.
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The processive actin polymerase VASP (vasodilator-stimulated phosphoprotein) is an 
important regulator of the organization of the actin cytoskeleton.1–3 VASP and its 
homologues, Mena and Evl, are involved in the formation of lamellipodia4 and filopodia,5,6 
as well as the cellular processes of phagocytosis,7 cell migration,3,4,8 and neuron axon 
guidance.9 VASP functions both as an actin polymerase and as an anti-capping 
protein,4,10,11 by protecting the barbed end of actin filaments from capping proteins. VASP 
and its homologues localize to specific sites in the cell such as lamellipodia and filopodia as 
well as focal adhesions and sites of stress fiber damage12–16 through binding to proline rich 
sequences with its EVH1 (Ena/VASP homology 1) domain.17,18
In response to cell mechanical stress, VASP is recruited to actin stress fibers, where it serves 
to reinforce and repair these highly regulated contractile structures.16 This is partially 
mediated by an interaction with Zyxin, a cytoskeletal protein involved in the mechanical 
stress response.15,16 Zyxin is phosphorylated at S142 in response to mechanical stimulation, 
which disrupts an inhibitory head–tail intramolecular interaction.19,20 Zyxin is then recruited 
to damaged stress fibers through an interaction between its LIM domains and unknown 
factors.21 Simultaneously, S142-phosphorylated Zyxin binds via multiple binding motifs in 
its disordered N-terminus to the proteins VASP and α-actinin.19
The interaction between VASP and Zyxin is mediated by both interactions between the N-
terminal proline rich region of Zyxin and the EVH1 domain of VASP and an interaction 
between the LIM domain region of Zyxin and the proline rich region of VASP.20 This allows 
the interaction to be regulated by phosphorylation at multiple sites. First, Zyxin can adopt an 
inhibited conformation in which its LIM domains obstruct its proline rich region, which can 
be destabilized by phosphorylation of S142 by Akt.19,20,22 Second, although the LIM–VASP 
interaction can overcome this inhibitory conformation, phosphorylation of VASP at S157 by 
PKA prevents this.20 Third, phosphorylation of Y39 in the EVH1 domain of VASP by Abl 
inhibits its interaction with Zyxin,23 though it is not clear why given the placement of Y39 
far from the EVH1 canonical binding site (here termed the primary binding site) known to 
bind the Listeria monocytogenes protein ActA.24
The VASP EVH1 domain binds the (W/F)PxφP motif, where x is any amino acid and φ is 
aliphatic.17,18 This motif most frequently occurs as FPPPP and very often occurs in clusters 
of four or five motifs, as in the cytoskeletal proteins lamellipodin and Zyxin, and ActA. This 
is thought to be a mechanism for enhancing binding between VASP and its binding partners, 
by combining the individual affinities of each of the four EVH1 domains in a VASP 
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tetramer.25 Indeed, deletions in the C-terminal region of the EVH2 domain in Ena (Ena-
VASP homology 2 domain) inhibit tetramerization and impair its ability to bind Zyxin in cell 
lysates26 and to localize VASP to focal adhesions.27 Inconsistent with this, however, are the 
facts that the EVH2 domain is dispensable for Listeria motility28 and that there seems to be 
a linear dependence of the rate of Listeria movement on the number of VASP binding sites 
in ActA.29 It has been proposed alternatively that a ligand molecule containing multiple 
FPPPP sites can be bound by multiple VASP tetramers, which would allow VASP to 
noncovalently cross-link its binding partners.25
Here, we provide evidence that a secondary binding site is present in the VASP EVH1 
domain. This secondary binding site interacts weakly with short peptides containing a single 
(W/F)PxφP motif but displays enhanced binding to a Zyxin fragment containing all four (W/
F)PxφP motifs. This enhancement could be created by Zyxin wrapping around the EVH1 
domain in analogy to the structures of the homologous WASP-EVH1/WIP30,31 and RanBP2-
RanBD1/Ran32 complexes. Analysis of nuclear magnetic resonance (NMR) titrations and of 
an EVH1–Zyxin chimera reveals a predominant orientation of the interaction, where the 
second FPPPP motif of Zyxin binds to the canonical binding site and a downstream region 
binds to the novel secondary binding site. This orientation was not observed when titrations 
were performed using the phosphomimetic EVH1 mutant Y39E, which demonstrates 
weakened or abolished binding at the secondary site. The secondary binding site influences 
the overall stoichiometry of the interaction between Zyxin and VASP, which provides 
insights regarding the effect of Y39 phosphorylation on the cellular localization of VASP.
MATERIALS AND METHODS
Protein Purification
EVH1 protein was expressed from a pMW172 vector with the human VASP EVH1 domain 
encoded (gift from M. Way, London Research Institute, London, U.K.) to produce a cleaved 
product consisting of EVH1 residues 2–115 with the non-native sequence GPGGRMS at the 
N-terminus. All proteins were expressed as previously described.33 The Y39E EVH1 
mutants were produced by using site-directed mutagenesis. A pDEST17 plasmid (ampicillin 
resistance) encoding human Zyxin residues 41–140, with an N-terminal six-His fusion and a 
TEV cleavage site, was produced using the GATEWAY cloning system (Thermo Fisher 
Scientific). The Zyxin41–140 sequence was amplified from a RFP-Zyxin expression vector 
purchased from Addgene (Addgene plasmid 2672034). All were purified using native 
preparations as described previously33 and dialyzed into NMR buffer [20 mM KHPO4 and 
50 mM KCl (pH 6.7)] following cleavage and removal of the His tag. NMR samples also 
contained 5 mM NaN3, 0.05% protease inhibitor cocktail (EDTA-free, Sigma), and 7% D2O. 
Unlabeled Zyxin41–140 protein used in the [15N]EVH1 titrations was concentrated to a 
volume of 600 μL, and a sample of 300 μL with 10 mM DSS was subjected to a one-
dimensional NMR experiment to determine by comparison to DSS the stock solution 
concentration. NMR samples were concentrated with 3000 MWC centrifugal concentrators. 
The protein concentration was determined by UV absorption at 280 nm, using the theoretical 
extinction coefficients of 21000 cm−1 M−1 for VASP EVH1 and 19500 cm−1 M−1 for VASP 
EVH1 Y39E.
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The EVH1 fusion protein with Zyxin was obtained by enzymatic digestion of the pMW172-
EVH1 vector with EcoRI and BLP1. Polymerase chain reaction amplification from 
pDEST17-Zyxin41–140 was performed to obtain the SSGSG-GGG linker followed by 
Zyxin82–124. After enzyme digestion, ligation to pMW172-EVH1 was performed using the 
ThermoScientific rapid ligation kit. Expression and purification were performed in the same 
way as they were for [15N]EVH1 but using media enriched with [13C]glucose.
Peptide Production
Synthetic peptides encompassing the individual motif in Zyxin, Zyxin69–80, Zyxin91–102, 
Zyxin102–113, and Zyxin112–123 were purchased from Genscript (Piscataway, NJ). Peptides 
were dissolved in NMR buffer, and their pHs were adjusted using NaOH. The peptide 
concentration was determined using the theoretical extinction coefficient of 195 cm−1 M−1 at 
257 nm.
NMR Data Collection and Processing
NMR experiments were performed at 25 °C using a Varian Inova 600 MHz spectrometer 
with a (H, C, N) Z-axis gradient probe. Spectra were processed with nmrPipe and analyzed 
with Sparky. Prior to Fourier transformation, [15N]EVH1 data were processed with an 
exponential window function. Peak positions and volumes were measured using the Sparky 
peak detection function.
Resonance Assignments
Resonance assignments for the EVH1 domain were obtained from the BioMagResBank, 
accession number 18569,18 and incongruent assignments or residues near the N-terminus 
were clarified by three-dimensional (3D) TOCSY and NOESY spectra of [15N]EVH1. 
Resonance assignments for the Y39E EVH1 mutant, and EVH1-Zyxin82–124, were obtained 
by 3D TOCSY and NOESY.
NMR Titration Experiments
Five [15N]EVH1-perspective HSQC and five [15N]Y39E EVH1-perspective HSQC titration 
experiments were performed. In each experiment, the sample with the highest concentration 
of Zyxin construct was produced first, and subsequent samples were produced by mixing 
part of the previous sample with a part of a stock of [15N]EVH1 or [15N]Y39E EVH1. The 
experiments were titrations of the [15N]EVH1 domain with Zyxin41–140, Zyxin69–80, 
Zyxin91–102, Zyxin102–113, and Zyxin112–123. In the Zyxin41–140 titration, the [15N]EVH1 
concentration was held to 0.21 mM and the Zyxin41–140 concentrations were 0, 0.02, 0.03, 
0.06, 0.13, 0.26, 0.52, and 1.03 mM. In the individual motif peptide titrations, the 
[15N]EVH1 concentration was held at 0.18 mM for all of them. Concentrations of 
Zyxin69–80 were 0, 0.15, 0.29, 0.59, 1.18, 2.35, 4.71, and 9.41 mM. In the Zyxin91–102 
titration, the peptide concentrations were 0, 0.08, 0.17, 0.34, 0.67, 1.34, 2.68, and 5.36 mM. 
For Zyxin102–113, the concentrations were 0, 0.14, 0.28, 0.56, 1.11, 2.22, and 4.45 mM, and 
for Zyxin112–123, they were 0, 0.25, 0.51, 1.02, 2.03, and 4.07 mM. The experiments for the 
phosphomimetic mutant were titration of [15N]Y39E EVH1 with Zyxin41–140, in which the 
[15N]Y39E EVH1 concentration was held to 0.23 mM and the Zyxin41–140 concentrations 
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were 0, 0.01, 0.03, 0.06, 0.12, 0.24, 0.49, and 0.97 mM. For the individual motif titrations, 
the [15N]Y39E EVH1 concentration was held at 0.18 mM and concentrations of Zyxin69–80 
were 0, 0.04, 0.08, 0.15, 0.31, 0.61, 1.23, 2.46, and 4.92 mM. The concentrations of 
Zyxin91–102 were 0, 0.10, 0.20, 0.40, 0.80, 1.60, 3.19, and 6.38 mM; those of Zyxin102–113 
were 0, 0.04, 0.08, 0.16, 0.32, 0.64, 1.28, 2.55, and 5.11 mM, and those of Zyxin112–123 
were 0, 0.09, 0.19, 0.37, 0.74, 1.49, 2.97, and 5.95 mM.
The [15N]EVH1 and [15N]Y39E EVH1 spectra were recorded with spectral widths of 8 kHz 
in the proton dimension (2048 complex data points) and 1.8 kHz in the nitrogen dimension 
(256 complex data points).
Quantification of Motif Binding in the Context of Zyxin41–140
TITAN offers a wide range of binding models that can be used for two-dimensional line 
shape analysis.35 For [15N]Y39E EVH1 titrated with individual motif peptides, we used the 
simple two-state interaction available in TITAN and simultaneously fit 10 peak profiles. 
Additionally, TITAN offers the flexibility of including personalized binding models. For the 
[15N]EVH1 wild type titrated with individual motif peptides, we used the four-state binding 
model described in detail elsewhere36 and fit 10 peak profiles in the primary binding site and 
six in the secondary binding site. Peaks included in these analyses were selected on the basis 
of trajectories that displayed maximum Δδ values that exceeded the corresponding error in 
Δδ by a factor of at least 10. The error in Δδ was determined on the basis of peaks that were 
insensitive to ligand addition, where the average standard deviations of positions of these 
“invariant” peaks in each of the proton and nitrogen dimensions were taken as the chemical 
shift uncertainty for all peaks, and standard error propagation was applied to obtain the 
corresponding error in Δδ. TITAN also has the option for a model with flexible 
stoichiometry, which we used to analyze the titration of [15N]EVH1 (WT/Y39E) titrated 
with Zyxin41–140. An error analysis was performed using 200 repeats to determine the 
uncertainties of the fitting.
To approximate the distribution of bound motif populations at the primary site for the 
[15N]EVH1 and [15N]Y39E EVH1 cases at the highest Zyxin41–140 concentration, an 
analysis of the observed chemical shift relative to the bound chemical shifts for each 
individual motif peptide was performed. An approximating assumption is that chemical shift 
perturbations in EVH1 due to binding of a given Zyxin motif are the same in the context of 
Zyxin41–140 versus the individual motif peptide. For this analysis, the observed chemical 
shifts (Δδobsmax i) for 10 residues (separately analyzed in nitrogen and proton dimensions), 
for which the peak trajectory directions of individual motif titrations differed the most, were 
used to solve for the bound motif populations using the following equation:
where P1–P4 represent the populations of the EVH1 domain bound to motifs M1P–M4P, 
respectively, P5 is the population of free EVH1, ΔδboundMji represents the fitted chemical 
shift of the bound state for given residue i determined for titrations with individual motif 
peptides (j = 1–4), and Δδapo,i is the chemical shift of residue i in the primary site of free 
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EVH1. With the additional constraint that the sum of Pi terms equals 1, Matlab was used to 
repeatedly solve the system of equations for eight residue-specific data sets selected 
randomly from a set of 20 data sets corresponding to the N and HN dimensions of 10 
primary binding site residues. The average and standard deviation were obtained from 500 
such runs. The same process was performed to approximate the bound motif populations in 
the most Zyxin41–140 -saturated [15N]Y39E EVH1 sample.
RESULTS
The Zyxin Proline Rich Region Induces Chemical Shift Changes at Expected and 
Unexpected Surfaces on VASP EVH1
The proline rich region of Zyxin that harbors its four VASP EVH1 binding motifs [Zyxin 
residues 41–140, Zyxin41–140 (Figure 1A)] was expressed and purified, and its interaction 
with VASP EVH1 was investigated using NMR spectroscopy. As a first step, the [15N]EVH1 
domain was titrated with unlabeled Zyxin41–140 (with the His tag cleaved) and a series of 
HSQC spectra were recorded. As expected, chemical shift perturbations were observed for 
residues previously characterized as being important for (W/F)PxφP ligand binding defined 
by the crystal structure of the Mena EVH1 domain/ActA complex and previous NMR 
studies of EVH1 titrated with (W/F)PxφP ligands.18,24,33 For example, residues W23, Y72, 
Q74, A75, W82, and N92 displayed large ligand-induced chemical shift changes (Figure 
1B,C). Remarkably, chemical shift perturbations were also observed for residues remote 
from this well-characterized binding site. Namely, residues Ser2, Val5, Ile6, Arg48, Val50, 
and Ala65 showed perturbations similar in magnitude to those of residues in the canonical 
binding site (Figure 1B,D). Mapping these chemical shift changes onto the EVH1 structure 
shows localization of these noncanonical binding residues on the opposite side of the 
domain (Figure 1E), suggesting the presence of a secondary binding site. The possibility of 
slight pH changes being responsible for this observation was ruled out by pH titration 
(Figure S1). This region has previously been implicated in function, as mutation of the 
nearby Y39 altered the co-localization of and interaction between VASP and Zyxin.23
Quantitative Analysis of the Interaction of [15N]EVH1 with the Zyxin Proline Rich Region 
Reveals a Bivalent Binding Mechanism
The detection of two binding sites on EVH1 that potentially interact with the multiple 
binding motifs on Zyxin41–140 significantly complicates the quantitative interpretation of the 
Zyxin41–140 titration data. To begin to decipher this interaction, four 12-residue synthetic 
peptides (M1P, Zyxin69–80; M2P, Zyxin91–102; M3P, Zyxin102–113; M4P, Zyxin112–123) were 
used in titrations of wild-type [15N]EVH1 to determine the intrinsic affinities of each motif 
under the same sample conditions and to determine the chemical shifts of residues in the 
EVH1 primary site when bound to each of the four Zyxin motifs. As expected, chemical 
shift perturbations at the primary binding site were observed. Additionally, chemical shift 
perturbations at the novel secondary binding site were induced by titration with all four 
peptides. Therefore, the binding affinity was determined using a four-state model (free 
[15N]EVH1, only primary site bound, only secondary site bound, and both primary and 
secondary sites bound) as previously described.36 For all four peptides, this analysis yielded 
relatively weak affinities for the primary binding site and considerably weaker affinities for 
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the secondary site (Table 1). These affinities are mostly weaker than the previously reported 
values for the same M1P–M4P peptides (74 μM, 61 μM, 197 μM, and no binding observed, 
respectively) determined by Trp fluorescence spectroscopy and fitted to a two-state model 
(free and 1:1 bound).18 It is possible that the affinity differences might be due to the lower 
pH (6.0) used in the Trp fluorescence measurements.18 Importantly, the NMR titration 
analysis yields motif-specific bound-state chemical shift values for residues in the primary 
binding site that are critical for characterizing the complex interaction between [15N]EVH1 
and Zyxin41–140.
The amide proton and nitrogen chemical shifts of a given amino acid residue in a system at 
equilibrium are a useful readout that can be used to determine the population distribution 
over multiple states for which distinct chemical shift values are known. With multiple 
residues serving as observers of the same set of states, complex equilibria can be 
characterized if the chemical shifts of the different states sampled by a given residue are 
sufficiently distinct. For the case at hand, several residues in the [15N]EVH1 primary 
binding site show distinct peak trajectories upon being titrated with M1P–M4P (Figure 2A), 
enabling populations of the bound Zyxin motifs in the context of Zyxin41–140 to be 
approximated by assuming the observed [15N]EVH1–Zyxin41–140 chemical shift is a 
population-weighted average of the apo and individual peptide-bound chemical shifts. This 
analysis shows a strong preference for binding of M2 in Zyxin41–140 to the primary site 
[∼6.4, 73.4, 9.3, 6.5, and 4.3% occupancy for motifs M1–M4 and apo, respectively (Figure 
2B)]. For comparison, Virtual Cell Modeling (VCell) software37 was used to simulate the 
expected population distribution for the most saturated [15N]EVH1–Zyxin41–140 sample 
condition if the four individual motifs in Zyxin were fully accessible and had the same 
intrinsic affinities as the corresponding short peptides (i.e., a 4:1 EVH1–Zyxin model). 
These simulations predict a significantly weaker preference of M2 binding [21, 35, 21, 19, 
and 4% occupancy for motifs M1–M4 and apo, respectively (Figure 2B)], indicating a 
significant impact of linking the four motifs together. Even if the simultaneous binding of 
EVH1 to nearest neighbor motifs is prohibited (i.e., all states with M1 and M2, M2 and M3, 
or M3 and M4 simultaneously bound are eliminated from the VCell model), the results are 
very similar (21, 35, 20, 19, and 5% occupancy for motifs M1–M4 and apo, respectively).
Taken together, the analyses described above demonstrate that Zyxin41–140 binds 
preferentially via M2 to the primary site, and that this binding mode is stabilized by 
interaction of another motif on the same Zyxin molecule with the secondary site to generate 
a bivalent bound state. This hypothesis is supported by an apparent enhancement of the 
primary site molar affinity compared to that seen with individual peptide titrations (Figure 
2C), and an even more pronounced affinity enhancement for the secondary binding site 
(Figure 2D). Bivalent additivity has been widely studied36,38,39 and, in this case, could 
significantly stabilize the 1:1 interaction between Zyxin and the VASP EVH1 domain.
Quantitative interpretation of the binding curves obtained from titration of [15N]EVH1 with 
Zyxin41–140 is approached by considering a highly simplified two-state model, in which a 
single Zyxin molecule interacts with a single EVH1 molecule, and this interaction involves 
both primary and secondary sites in one unique Zyxin orientation. In this model, the 
apparent affinity enhancement of Zyxin41–140 relative to those of individual motif peptides 
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would be due to the combined binding energies of both primary and secondary surfaces. 
Fitting of the binding data for six residues in the primary and six residues in the secondary 
binding surface to this model yields an apparent Kd value of 32.2 ± 1.7 μM (Figure 2E). The 
goodness of fit, evaluated by a χ2 analysis as described in detail elsewhere,36 yielded a 
reduced χ2 value of 4.19. This χ2 value is consistent with the two-state bivalent model being 
an oversimplification, as expected because the population distribution determined above 
indicates that multiple bound species are sampled. Separate fitting of just the primary or 
secondary site residues to the simple two-state model yields apparent Kd values of 21.8 ± 1.3 
and 133.3 ± 5.8 μM for the primary and secondary sites, respectively, with corresponding χ2 
values of 0.25 and 1.55 indicating good fits. The significant increases in affinity of both 
independently fitted primary and secondary site Kd values relative to the individual motif 
peptides, together with the overall affinity enhancement reflected in the highly simplified 
two-state bivalent fitting, are consistent with a more complex multistate model in which a 
dominantly populated bivalent state contributes to a significant enhancement of affinity. 
Additionally, the population distribution deduced from chemical shift perturbations supports 
a bivalently bound state with M2 bound to the primary site and a downstream epitope bound 
to the secondary site.
EVH1–Zyxin82–124 Fusion Protein Captures the Bivalently Bound State
To confirm that both primary and secondary sites are dominantly bound in a 1:1 
stoichiometry in a bivalent manner, a fusion protein was constructed in which the C-
terminus of EVH1 is fused to the proline rich region of Zyxin containing motifs M2–M4 
[EVH1–Zyxin82–124 (Figure 2F)]. Importantly, no significant changes in [15N]EVH1 peak 
line widths were observed relative to WT EVH1, indicating the chimera is a monomer and 
not a domain-swapped dimer. Moreover, no NOESY crosspeaks were detected between the 
Zyxin and EVH1 components of the chimera, consistent with highly dynamic interfaces as 
expected from the weak intrinsic affinities characterized above. Resonance assignments for 
the EVH1 domain segment of the chimera were confirmed by standard triple-resonance 
NMR experiments. The 15N–1H HSQC spectrum of the 15N- and 13C-labeled EVH1–
Zyxin82–124 chimera shows peak positions in both primary and secondary binding sites that 
are consistent with a more saturated state of the same binding trajectory as observed during 
titration with Zyxin41–140 (Figure 2A,G). This coincidence of the forced 1:1 stoichiometry in 
the chimera and the titration with Zyxin41–140 further justifies the bivalent model employed 
above for quantitative analysis of the Zyxin41–140 titration data. While the primary site 
shows a clear preference for M2 based on chemical shifts, it is not possible to distinguish a 
motif preference at the secondary site from the [15N]EVH1 perspective due to the lack of 
distinct chemical shift trajectories and the weak affinities of the individual motif peptides 
that prevented observation of larger populations of bound states (Figure 2G).
The Phosphomimetic EVH1 Y39E Mutation Induces Changes in the Remote Primary 
Binding Site and Abolishes Binding to the Secondary Site
It has been reported that phosphorylation of Y39 by Abl reduced the level of VASP 
accumulation in focal adhesions, and that mutation of Y39 to aspartic acid reduced the level 
of binding of VASP to Zyxin and altered cellular localization.23 Because Y39 is located 
within the secondary binding site described above (Figure 1E), we wondered whether 
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placement of a negative charge at the Y39 position would inhibit binding at the EVH1 
secondary site, thereby eliminating bivalent binding. Bacterial expression of EVH1 Y39D 
was poor (unpublished data), while EVH1 Y39E was robustly expressed and stable in 
aqueous solution. Therefore, EVH1 Y39E was used for phosphomimetic investigations, and 
backbone resonance assignments for this mutant (BioMagResBank entry 27193) were 
determined using a standard suite of 3D NMR experiments.40
To investigate whether the Y39E mutation alters the interaction of EVH1 with the Zyxin 
proline rich region, we first performed titrations with each of the four individual Zyxin motif 
peptides. Notably, significant chemical shift perturbations were observed for only residues of 
[15N]EVH1 Y39E in the primary binding site and not in the secondary site, indicating that 
indeed placement of a negative charge at residue 39 inhibits binding at the secondary site. 
Primary site binding affinities for each peptide, determined using a simple two-state binding 
model, are again relatively weak as was found in wild-type EVH1 (Table 2).
Next, Zyxin41–140 was titrated into [15N]EVH1 Y39E. While significant chemical shift 
changes in the primary binding site were observed, only minimal chemical shift 
perturbations were observed for residues at the secondary binding site, indicating a loss of 
the bivalent bound state (Figure 3). Consistent with this, the resulting binding curves for 
residues in the primary site could not be adequately fit to a simple two-state (1:1 
stoichiometry) model (reduced χ2 value of 36.47), suggesting two or more EVH1 domains 
may bind to a single Zyxin molecule if a dominant 1:1 state is not achievable.
A key difference between the titrations of [15N]EVH1 WT and [15N]EVH1 Y39E is that the 
chemical shift trajectories differ (Figure 3B compared to Figure 1C). This difference can be 
explained by an altered population distribution of bound motifs. As was observed for WT 
EVH1, several residues in the [15N]EVH1 Y39E primary binding site show distinct peak 
trajectories upon being titrated with M1P–M4P, again enabling populations of the bound 
Zyxin motifs in the context of [15N]EVH1 Y39E with the most concentrated Zyxin41–140 
condition to be approximated (Figure 4A). Strikingly, the populations were 16, 44, 20, 14, 
and 6% occupancy for motifs M1–M4 and apo, respectively, far more similar to the VCell-
simulated population distribution for EVH1 Y39E based on individual motif peptide Kd 
values (simulation values of 22, 32, 23, 18, and 5% occupied by motifs M1–M4 and apo, 
respectively). Moreover, chemical shift perturbations induced by titration with Zyxin41–140 
indicate binding at the primary but not at the secondary binding sites (Figures 3B–D and 
4B,C). Together, these results demonstrate that the Y39E phosphomimetic mutation 
effectively abolishes the bivalent binding mode and enables the four motifs in Zyxin to 
interact with the primary binding site of EVH1 in a more equal population distribution. 
These results suggest that Y39 phosphorylation might act as a binding mode switch, where 
EVH1 domains with unphosphorylated Y39 bind to Zyxin predominantly in a bivalent 1:1 
stoichiometry, and upon phosphorylation of tyrosine, up to four EVH1 domains could bind 
to one molecule of Zyxin.
To investigate potential phosphorylation-induced allostery, we focused our attention on the 
backbone chemical shift assignments of the phosphomimetic EVH1 Y39E mutant. The 
peaks corresponding to N-terminal residues S2–C7 move in response to the Y39E 
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phosphomimetic mutation, consistent with the structural interaction between Y39 and this 
region revealed in the NMR structure of human VASP EVH118 (1EGX and its homologues). 
Other residues in sequential or spatial proximity to Y39 also display new peak positions, 
such as H40, F47, and V49 (Figure 5), as expected. However, there are several residues more 
than 14 Å from the mutation site that display altered backbone and/or side chain NH 
chemical shifts. Striking examples include residues that reside in the primary binding site of 
EVH1, such as W82, A85, and W89 (Figure 5A). Mapping of the backbone NH chemical 
shift differences between WT and Y39E EVH1 onto the structure reveals a clear 
perturbation pathway from the mutation site to these residues (Figure 5B). These long-range 
perturbations of chemical environment induced by the phosphomimetic Y39E mutation 
suggest that phosphorylation of Tyr39 could similarly trigger a conformational 
rearrangement that alters the primary binding site of EVH1.
DISCUSSION
Understanding protein–protein interaction mechanisms that fine-tune signaling pathways is 
an important endeavor in biology. Here we studied the interaction between the EVH1 
domain of VASP and the proline rich region of Zyxin. This interaction plays a critical role in 
the localization of VASP in focal adhesions.41 Interestingly, VASP mislocalization is 
achieved only when all four FPxφP motifs of Zyxin are compromised,42 showing that indeed 
these motifs mediate this interaction. VASP differs from MENA and EVL in its regulation 
by phosphorylation at Y39.23 Here, through application of NMR, we found a secondary 
binding site near Y39 in the VASP EVH1 domain that, along with the canonical EVH1 
binding site, contributes to the interaction with the proline rich region of Zyxin. This 
secondary binding site is abolished by phosphomimetic mutation of Tyr39 to Glu. These 
studies suggest that Y39 phosphorylation acts as a stoichiometry switch, with one molecule 
of Zyxin binding to one EVH1 domain in the unphosphorylated state, and one molecule of 
Zyxin potentially binding to multiple EVH1 domains in the phosphorylated state.
Support for the biological relevance of the secondary binding interaction described here 
comes from the reported impact of phosphorylation of VASP EVH1 by Abl tyrosine 
kinase.23 In Bcr-Abl-positive leukemic cells, Abl phosphorylates Y39 of VASP, which is 
centrally located in the binding site we describe (Figure 1E). This may regulate the 
interaction between VASP and Zyxin, because the phosphomimetic mutant Y39D has a 
weakened ability to bind Zyxin in pull downs. Furthermore, overexpression of the Y39D or 
Y39F mutant, but not WT VASP, impairs adhesion of K562 cells to fibronectin, implying 
that a cycle of phosphorylation and dephosphorization is important for the proper regulation 
of VASP.23 Here, we provide evidence that the Y39E mutant of VASP EVH1 retains WT 
binding affinity for its primary site but is incapable of binding in the secondary site. 
Importantly, we show that this phosphomimetic mutation switches the stoichiometry of the 
interaction. Taken together, these data suggest that the secondary binding site could play a 
key role in the phosphorylation and dephosphorization cycle of VASP to regulate 
interactions with Zyxin and other proline rich binding partners.
EVH1 domains all share a conserved primary binding site that binds proline rich sequences 
adopting a polyproline type II (PPII) structure. The canonical (primary) binding site is a 
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concave surface formed by one of the two β-sheets that form the domain’s β-sandwich fold 
(Figure 6, right). The secondary binding site we define here is a similar concave surface 
formed by the other β-sheet on the opposite side of the domain. The residues most sensitive 
to the secondary interaction include the very N-terminal sequence of EVH1 (M0-C7) as well 
as the side chains of R48, and N63, which are all near each other (Figure 6, right). Although 
interactions beyond the primary site have been reported,18,30 these additional EVH1 sites are 
highly distinct from the secondary binding surface described here.
EVH1 domains are homologous in structure and sequence with RanBDs.43 The crystal 
structure of the first RanBD (denoted RanBD1) in RanBP2 bound to the nuclear transport 
protein Ran demonstrates that key features of the secondary binding site in VASP EVH1 are 
conserved in RanBDs.32 In this structure, a segment of Ran binds to the face of RanBD1 that 
corresponds to the secondary binding site we have described (Figure 6, left). The side chains 
of RanBP2 residues R77, R81, and N91 (corresponding to VASP EVH1 residues R48, R52, 
and N63, respectively) hydrogen bond with the backbone carbonyl groups of residues M179, 
A181, and L182 in Ran that are part of a PPII segment. Alignment of EVH1 and Ran 
binding domains shows that R48 and N63 are highly conserved,43 suggesting even broader 
utilization of this secondary binding site (e.g., by EVH1 domains in WASP and Homer). 
Importantly, the binding of a PPII structure to the corresponding “secondary site” in 
RanBD1 and the conservation of key interaction residues in EVH1 domains suggest that the 
EVH1 secondary site identified here might bind to sequences that adopt the PPII structure 
without the requirement of the W/FP motif.
VASP EVH1 has several binding partners that contain multiple proline rich motifs, some of 
which lack the canonical W/FPxφP primary site recognition motif. For instance, the Lipoma 
preferred partner (LPP), which is implicated in cell shape and motility, has two proline rich 
motifs (66DFLPPPP-PPLD76 and 87NFPPPPPLD95, only one of which has the canonical 
motif) separated by 12 residues, and direct binding of VASP EVH1 was previously 
reported.44 Similarly, Vinculin, a known EVH1 binding partner,45 has only one FPxφP motif 
(842FPPPPP847) but has another proline rich motif nearby (859APPKPPLP866). Even more 
surprising is Migfilin, a component in cell-matrix adhesions that offers a link with the actin 
cytoskeleton.46 Migfilin regulates localization of VASP to the cell-matrix adhesions via its 
proline rich region that interacts directly with the VASP EVH1 domain. Deletion of residues 
84–112 in Migfillin eliminates VASP binding.47 Interestingly, this deletion contains two 
proline rich motifs without W or F (85CPPPPP90 and 104LPPPPPPPP112) separated by 14 
residues. All of these proline rich motifs are expected to adopt PPII structure, which 
potentially could bind to the secondary binding site. Notably, the presence of neighboring 
proline rich motifs could enhance dramatically the affinity through bivalent binding as 
observed here for Zyxin.
It is well established that VASP functions in the cell as a constitutive tetramer.48 Four VASP 
polypeptide chains associate via the single-helix tetramerization domain to form a parallel 
right-handed four-helix coiled coil, causing VASP to form a “bouquet-like” tetramer.49 
Truncation of the C-terminal region of VASP that contains the tetramerization domain 
causes a decrease in the VASP concentration at focal adhesions, indicating a tetramerization 
dependence for focal adhesion localization.27 Moreover, the possibility of VASP cross-
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linking several protein partners has been previously discussed.25 Notably, the work 
presented here suggests that when VASP residue Y39 is not phosphorylated, the bivalent 
interaction between one EVH1 domain and one multivalent protein ligand could allow a 
VASP tetramer to tightly localize as many as four different binding partners, effectively 
achieving reversible cross-linking of these partners (Figure 7A). Moreover, when VASP is 
phosphorylated at Y39, the resulting loss of secondary site binding would promote 
interaction of the VASP tetramer with a single multivalent protein partner due to the 
enhancement of avidity (Figure 7B). We propose a model in which Y39 phosphorylation 
acts as a molecular switch that governs the stoichiometry of interactions between the VASP 
tetramer and its binding partners that harbor multiple FPxφP motifs, where the 
unphosphorylated state acts as a cross-linker between multiple partners while the 
phosphorylated state binds to a single partner (Figure 7).
In summary, a secondary binding site in the VASP EVH1 domain was identified and 
characterized through NMR investigations of the interactions between the proline rich region 
of Zyxin and [15N]EVH1. By analysis of population distributions over bound states, we 
determined that this secondary binding site directs the orientation of Zyxin binding through 
formation of a bivalent interaction between Zyxin and EVH1. In this bivalently bound state, 
M2 in Zyxin interacts with the primary site and downstream Zyxin regions interact with the 
secondary site in EVH1. Additionally, we observed that the secondary binding site is 
abolished by phosphomimetic mutation of Y39 to E. Phosphorylation dependence at Y39 for 
the interaction between VASP and Zyxin has been previously reported.23 On the basis of our 
findings, we hypothesize that phosphorylation of Y39 acts as a stoichiometry switch in the 
interaction between the VASP tetramer and Zyxin. These results have important implications 
for the regulation of VASP interactions with its other binding partners that contain multiple 
neighboring proline rich motifs, and more broadly for potential regulation of interactions 
involving other EVH1 domains in which residues implicated in secondary site function are 
conserved.
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Figure 1. 
Zyxin41–140 titration provides evidence of a secondary binding site in the EVH1 domain of 
VASP. (A) Amino acid sequence of the Zyxin41–140 construct, highlighting the four VASP 
binding motifs (red, bold type). (B) Composite chemical shift changes in [15N]EVH1 
induced by addition of Zyxin41–140, calculated using the equation 
. Extracted regions of overlays of 15N–1H HSQC spectra of 
[15N]EVH1 titrated with Zyxin41–140 show trajectories for residues in (C) the canonical 
binding site and (D) a novel secondary site, all of which show maximum Δδ values in excess 
of 10 times the error in Δδ (determined to be 0.005). (E) Chemical shift changes mapped 
onto the structure of VASP EVH1 (Protein Data Bank entry 1EGX) show that Zyxin41–140 
induces chemical shift perturbations for residues in the primary binding site (far right) but 
also for residues on the opposite face of the EVH1 domain (far left). Red denotes the largest 
chemical shift perturbation and purple no perturbation.
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Figure 2. 
Secondary binding site that creates a larger population of motif 2 bound to the canonical 
binding site. (A) Titrations show distinct chemical shift peak trajectories upon addition of 
each motif peptide (yellow, M1P; red, M2P; green, M3P; blue, M4P). The magenta peak 
shows titration with Zyxin41–140 at the highest Zyxin concentration. Purple shows the 
chemical shift of chimeric EVH1-Zyxin. (B) Distribution of Zyxin41–140 motifs bound at the 
canonical site of EVH1 deduced from chemical shifts (filled circles) compared with the 
expected distribution based on Kd values of individual peptides (stars). (C) Binding curves 
from average normalized chemical shift changes of 10 residues in the canonical binding site 
of EVH1 for individual peptide titrations and for Zyxin41–140. The yellow binding curve 
indicates titration with M1P, the red binding curve titration of EVH1 with M2P, the green 
binding curve titration of EVH1 with M3P, the blue binding curve titration of EVH1 with 
M4P, and the purple binding curve titration of EVH1 with Zyxin41–140. (D) Like panel C, for 
six residues at the novel secondary binding site of EVH1. (E) Binding curve from average 
normalized chemical shift changes for the primary binding site (blue dots) and for the 
secondary binding site (red dots) and a global fit to both curves (Kd = 32.2 μM). (F) Chimera 
of EVH1 and Zyxin (EVH1–Zyxin82–124) containing M2 (red), M3 (green), and M4 (blue) 
motifs. (G) Overlays of 15N–1H HSQC spectra for residues in the noncanonical site, titrated 
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with M2P (red), M3P (green), M4P (green), or Zyxin41–140 (magenta) or in the context of 
EVH1–Zyxin82–124 (purple).
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Figure 3. 
Phosphomimetic mutation abolishes secondary site binding. (A) Bar plot showing 
differences between composite chemical shift perturbations of the 1H and 15N resonances 
upon addition of Zyxin41–140 to EVH1 WT and EVH1 Y39E. Those residues with the 
largest perturbation differences are located in the novel secondary binding site. Overlays 
of 15N–1H HSQC spectra for residues in (B) the canonical binding site and (C) the 
secondary site show binding for the primary but not secondary sites. (D) Mapping chemical 
shift changes induced by titration of [15N]EVH1 Y39E with Zyxin41–140 onto the structure 
of the VASP EVH1 domain (Protein Data Bank entry 1EGX) shows large perturbations for 
residues in the primary binding site (far right) but almost no perturbations for residues on the 
opposite face of the EVH1 Y39E domain (far left). Red indicates the largest chemical shift 
perturbation and purple no perturbation.
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Figure 4. 
Population and binding curves for [15N]EVH1 Y39E. (A) Distribution of Zyxin41–140 motifs 
bound at the canonical site of EVH1 Y39E deduced from chemical shifts (filled circles) 
compared with the expected distribution based on Kd values of individual peptides (black 
crosses). (B) Binding curves from average normalized chemical shift changes of 10 residues 
in the canonical binding site of EVH1 Y39E for individual peptide titrations and for 
Zyxin41–140. The yellow binding curve indicates titration with M1P, the red binding curve 
titration of EVH1 Y39E with M2P, the green binding curve titration of EVH1 Y39E with 
M3P, the blue binding curve titration of EVH1 Y39E with M4P, and the purple binding 
curve titration of EVH1 Y39E with Zyxin41–140. (C) Like panel B, for six residues at the 
novel secondary binding site of EVH1 Y39E.
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Figure 5. 
1H–15N chemical shift differences between wild-type EVH1 and mutant Y39E. (A) 
Chemical shift differences between wild-type EVH1 (blue spectra) and EVH1 Y39E (red 
spectra). Both spectra were recorded under identical buffer conditions and with the same 
parameters. All highlighted residues display differences in chemical shift that exceed the 
error in chemical shift value by a factor of at least 10. (B) Mapping of 1H–15N backbone 
chemical shift differences to the EVH1 structure. Significant changes (>0.25 ppm) are 
represented by red, and no change is shown as purple.
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Figure 6. 
Tyr39 is located centrally in the secondary EVH1 binding site. In the left panel, the first Ran 
binding domain of RanBP2 (orange) binds Ran (cyan) using a secondary binding surface 
similar to the site we describe, employing residues R77, R81, and N91 that correspond to 
R48, R52, and N63, respectively, in VASP EVH1 (Protein Data Bank entry 1RRP). In the 
right panel, VASP EVH1 residue Y39 is located centrally in the secondary binding site. 
EVH1 is colored according to chemical shift perturbations induced by Zyxin41–140 (green, 
no perturbation; yellow, largest perturbation). Key residues are shown as sticks. The ActA 
sequence FPPPP (yellow) is shown bound in the primary site.
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Figure 7. 
Proposed model for the stoichiometry switch controlled by phosphorylation of Y39 in VASP 
tetramers. (A) In the extreme case where all Y39 residues are unphosphorylated, each EVH1 
domain in the VASP tetramer could interact with a molecule of Zyxin or any other binding 
partner. Bivalent interactions could form due to the presence of nearby proline rich motifs. 
(B) In the extreme case where each Y39 residue is phosphorylated (purple stars), one 
molecule with multiple FPxφP motifs (like Zyxin, ActA, or lammellipodin) could bind to 
one tetramer of VASP. Phosphorylation of Y39 could recruit VASP exclusively to a specific 
binding partner with multiple canonical binding sites, while dephosphorylation could cause 
cross-linking between multiple binding partners.
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Table 1
Dissociation Constants Calculated for EVH1 Primary and Secondary Binding Sites Titrated with Different 
Zyxin Peptides
 (μM)
 (mM)
M1P 237 ± 2 4.5 ± 0.1 0.82
M2P 134 ± 2 4.4 ± 0.2 0.96
M3P 235 ± 3 9.8 ± 0.3 1.50
M4P 263 ± 3 2.1 ± 0.1 1.26
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Table 2
Dissociation Constants for the Primary Binding Site in Y39E EVH1
Kdprimary (μM) Xred2
M1P 176 ± 2 0.91
M2P 126 ± 2 0.99
M3P 182 ± 2 0.84
M4P 240 ± 1 0.54
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